Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease

Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)

The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.

To test in a single blind randomized control study the efficacy of Rituximab versus combination of pulse cyclophosphamide and azathioprine. Both group receiving 0.5 mg/kg/daily prednisolone.

Inclusion Criteria:

• Behcet's Disease fulfilling the new International Criteria for Behcet's Disease
• Having active ocular lesions (posterior and/or retinal vasculitis)
• Resistant to cytotoxic drugs + prednisolone 0.5 mg/kg

Exclusion Criteria:

• Visual acuity less than 1/10 on Snellen chart
• Antecedent of allergic reaction to any component of the therapeutic regimen